AVEANNA HEALTHCARE HOLDINGS INC (AVAH)
Health Care · Home Healthcare Services · NASDAQ
Aveanna Healthcare is a leading provider of comprehensive home-based healthcare services, focusing on specialized clinical and supportive care for patients.
What AVEANNA HEALTHCARE HOLDINGS INC does
Aveanna Healthcare Holdings provides specialized home-based healthcare services, including clinical, rehabilitative, and supportive care. Its service offerings span private duty nursing, home health and hospice care, and the provision of durable medical equipment.
Themes: home healthcare, hospice services, private duty nursing, value-based care
Fundamentals
- Price$12.24 as of 2026-10-08 close
- Market cap$2.7B as of 2026-08-07 (share count; price 2026-10-08)
- 1-year return+36.8% 2025-10-08 close $8.95 → 2026-10-08 close $12.24
- P/E10.40 as of 2026-10-08
- Net margin+9.2% FY2026, SEC XBRL
- Gross margin+33.3% FY2026, SEC XBRL
- ROE+115.7% FY2026, SEC XBRL
- Debt / equity6.07 as of 2026-09-03
- Revenue growth (YoY)+20.5% as of 2026-09-03
- Revenue CAGR (3y)+8.0% SEC XBRL
- Beta0.93 as of 2026-09-03
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How AVAH compares in its sector
- price-to-earnings ratiobottom 10% 185 covered Health Care peers, as of 2026-10-08
- net profit margintop 25% 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- gross marginbottom 25% 189 covered Health Care peers, as of 2026-09-03
- return on equitytop 10% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
AVAH is not currently in any published Top 10 list. Its scores are below.
Top 10 score
51.6 #641 of 1,379 scored · #79 of 151 in Health Care
Profitability 72nd (return on equity 115.7%, operating margin 10.5%) and growth 66th (revenue growth year over year 20.5%, 3-year revenue CAGR 8%); weakest is financial health (9th, debt to equity 6.1, free cash flow margin -3.6%).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How AVEANNA HEALTHCARE HOLDINGS INC looks technically
AVEANNA HEALTHCARE HOLDINGS INC (AVAH) is trading 36.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 54 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 41, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 3 trading days ago. It is 16.8% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 36.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +36.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $12.39 | $12.39 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $8.95 | $8.95 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 13 calendar days ago — the swings before that are what the structure reading is measured on | 13 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 54 trading days ago — a "golden cross", a bullish long-term signal | 54 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with sellers in control | 25.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 41, neither overbought (above 70) nor oversold (below 30) | 41.1 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($12.00 to $13.72) — its "stochastic" reading is 14 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 13.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 26 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $14.71 | $14.71 |
|---|---|---|
| From the 52-week high | it is 16.8% below its 52-week high (its highest price of the past year) | -16.8% |
| Above the 52-week low | it is 106.4% above its 52-week low (its lowest price of the past year) | +106.4% |
| Below the 52-week high | it is 16.8% below its highest point of the past year | 16.8% |
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 19 trading days ago | 19 sessions |
| All-time high | its highest closing price on record is $14.71 (set on 2026-09-16) | $14.71 |
| Given back of the 52-week move | over the past year its closes ranged ($6.22 to $14.38), and it has given back roughly a quarter of its rise from last year’s low — 26% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $9.08 to $9.34. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 26.2% |
| From the all-time high | it is 16.8% below its all-time high | -16.8% |
| Nearest price level | it is trading 18.2% above a support level at $10.01 — a price it turned at three times since 2025-10-29, most recently on 2026-07-29. Since 2024-10-08 it has 11 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -18.2% |
| All-time low | its lowest closing price on record is $0.6664 (set on 2022-12-30) | $0.6664 |
| Above the all-time low | it is 1736.7% above its all-time low | +1,737% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 62nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4859 between its high and its low — about 4.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4859 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $11.51 and $14.58 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $11.51 – $13.05 – $14.58 |
| Typical daily range (% of price) | its price moves about 4.0% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.0% |
| Stretch from the 200-day average | it is trading 6.8 daily ranges above its 200-day average price (36.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.8 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.75× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bearish engulfing | 3 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 3 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.6% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.6% |
|---|---|---|
| Open gap | it gapped 3.8% below the previous close 6 sessions ago and has not traded back through the level it left behind at 12.78 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -3.8% |
| Gap filled | a 2.4% gap up opened on 2026-08-24 has been "filled" 27 sessions ago — price traded back through the level the gap left behind, and it took 5 sessions to close | 27 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 11.4 percentage points (the stock lost 10.4% while the market gained 1.0%) | -11.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 23.8 percentage points (the stock gained 27.6% while the market gained 3.8%) | +23.8% |
| vs market, 6 months | over the past 6 months this stock beat the market by 71.1 percentage points (the stock gained 88.6% while the market gained 17.5%) | +71.2% |
| vs market, 12 months | over the past 12 months this stock beat the market by 21.8 percentage points (the stock gained 36.8% while the market gained 15.0%) | +21.8% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 12.2% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 23% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $9.98 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | +22.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% below the average price paid since it last reported on 2026-08-13 (its 10-Q), so the typical buyer over that stretch is under water. That average is $13.05 — a volume-weighted average of daily closes over 40 sessions, not a true tick-by-tick VWAP. | -6.2% |
Price levels it has turned at before
AVAH last closed at $12.24 on 2026-10-08. Since 2024-10-08 it has turned at 11 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $10.01 | Support | 18.2% below the last close | turned there three times · 2025-10-29 to 2026-07-29 |
| $9.00 | Support | 26.5% below the last close | turned there three times · 2025-10-01 to 2026-07-23 |
| $8.72 | Support | 28.8% below the last close | turned there four times · 2025-09-18 to 2026-08-12 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke down to a new 20-day low · beating the market · Printed a doji candle · Stretched far above its 200-day average (6+ daily ranges) · At the bottom of its 14-day range (stochastic below 20) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$14.60 range $13.00 – $16.00; median $15.00
Analyst estimates, as of 2026-10-06. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AVAH
- Consensus EPS estimate$0.2069 next reporting period, as of 2026-10-06
- Estimate change, 30 days-$0.00216 (-1.0%) from $0.2091, on 2026-09-01, 35-day window
- Readings revised upward43% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Substantial indebtedness which limits financial flexibility and reaction to market changes.","Heavy reliance on government reimbursement programs (Medicare/Medicaid) and potential for adverse rate changes or payment model shifts.","Intense competition for qualified healthcare personnel and in the broader home healthcare market."]
What changed in the latest 10-Q
AI-assisted comparison of AVAH's 10-Q filed 2026-08-13 against the prior one filed 2026-05-14.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-13) adds fiscal period definitions for the second quarter and first six months of 2026 and 2025: 'three-month period ended July 4, 2026' / 'second quarter of 2026' (13-week quarter ended July 4, 2026), 'three-month period ended June 28, 2025' / 'second quarter of 2025' (13-week quarter ended June 28, 2025), 'six-month period ended July 4, 2026' / 'first six months of 2026' (January 4, 2026 through July 4, 2026), and 'six-month period ended June 28, 2025' / 'first six months of 2025' (December 29, 2024 through June 28, 2025).
- Newer filing (2026-08-13) adds a revenue table for the six-month periods ended July 4, 2026 and June 28, 2025, showing consolidated revenue of $1,318,398 thousand (PDS $1,089,581, HHH $135,632, MS $93,185) for 2026 with segment percentages of 83%, 10%, 7%, and consolidated revenue of $1,148,777 thousand (PDS $946,010, HHH $116,845, MS $85,922) for 2025 with segment percentages of 82%, 10%, 8%.
- Removed:
- Older filing (2026-05-14) contains fiscal period definitions for the first quarter of 2026 and 2025: 'three-month period ended April 4, 2026' / 'first quarter of 2026' (13-week quarter ended April 4, 2026) and 'three-month period ended March 29, 2025' / 'first quarter of 2025' (13-week quarter ended March 29, 2025); these definitions do not appear in the newer filing.
- Reworded:
- Older filing (2026-05-14) revenue table covers the three-month periods ended April 4, 2026 and March 29, 2025, with consolidated revenue of $647,915 thousand (PDS $535,652, HHH $66,609, MS $45,654) for 2026 and $559,224 thousand (PDS $459,998, HHH $56,733, MS $42,493) for 2025; newer filing (2026-08-13) revenue table for the three-month period instead covers quarters ended July 4, 2026 and June 28, 2025, with consolidated revenue of $670,483 thousand (PDS $553,929, HHH $69,023, MS $47,531) for 2026 and $589,553 thousand (PDS $486,012, HHH $60,112, MS $43,429) for 2025.
- Older filing (2026-05-14) includes the sentence 'Through our care, we help our patients recover more fully in the comfort of their own homes, while remaining as independent as possible. HH Services include: in-home skilled nursing services; physical, occupational and speech therapy; medical social services and aide services.' following the HH Services description; newer filing (2026-08-13) text appears truncated at '...help our patients recover more fully in the comfort of their own home' and does not show the completed sentence or the HH Services list.
- Older filing (2026-05-14) includes additional text beginning 'Our hospice services invo lve a supportive philosophy...' after the HH Services paragraph; the newer filing (2026-08-13) excerpt ends before this hospice services text.
- Notes:
- The newer filing excerpt appears truncated mid-sentence in the HH Services section ('...comfort of their own home'), so later portions of the newer MD&A are not available for comparison.
- Page numbering differs between the two filings (newer shows '19', older shows '17' at similar points in the text).
- Only the portions of the MD&A provided in the excerpts were compared; any changes outside these excerpts are not addressed.
Risk Factors
- Added:
- In the newer filing filed 2026-08-13, the Risk Factors section's Item 5 (Other Information) includes disclosure of a Rule 10b5-1 trading arrangement adopted on May 28, 2026 by Patrick A. Cunningham, Chief Compliance Officer, for eligible sell-to-cover transactions with an aggregate of 28,373 securities to be sold, along with footnotes (1), (2), and (3) explaining the plan terms.
- In the newer filing filed 2026-08-13, an explanatory paragraph was added after the 10b5-1 plan table stating that the officer provided a representation to the Company, in accordance with the Company's securities trading policy, that the individual was not in possession of any material nonpublic information on the date of adoption.
- In the newer filing filed 2026-08-13, Exhibit 10.1 for the Thirteenth Amendment to First Lien Credit Agreement dated as of May 26, 2026 was added to the exhibit list.
- In the newer filing filed 2026-08-13, Exhibit 10.2 for the Eighth Amendment to the Receivables Financing Agreement dated June 25, 2026 was added to the exhibit list.
- In the newer filing filed 2026-08-13, a footnote indicated by '**' was added stating that pursuant to item 601(a)(5) of Regulation S-K, certain exhibits and schedules to the agreement have been omitted, and the registrant agrees to furnish supplementally to the SEC a copy of any omitted exhibits or schedule upon request.
- Removed:
- In the older filing filed 2026-05-14, the Risk Factors section's Item 5 (Other Information) disclosed that none of the directors or officers adopted, modified, or terminated any Rule 10b5-1 trading arrangement during the quarter ended April 4, 2026; this statement of no activity is absent from the newer filing filed 2026-08-13, which instead discloses the May 28, 2026 plan adoption.
- Reworded:
- In the newer filing filed 2026-08-13, Item 5 (Other Information) references the quarter ended July 4, 2026, whereas the older filing filed 2026-05-14 references the quarter ended April 4, 2026.
- In the newer filing filed 2026-08-13, Item 5 (Other Information) states 'none of the directors or officers of the Company adopted, modified, or terminated'... followed by 'except as follows' with the plan disclosure, whereas the older filing filed 2026-05-14 ends the sentence without any exceptions.
- In the older filing filed 2026-05-14, the term 'non-Rule 10b5-1 trading arrangement' is enclosed in curly quotes (“ ”), whereas the newer filing filed 2026-08-13 uses straight quotes for the same term.
- Notes:
- The Risk Factors section itself (Item 1A) is identical in both filings; all noted changes relate to subsequent items within the provided text (Item 5, Item 6).
- The newer filing text includes 'Equi ty' and 'Safe ty' with spacing artifacts, which appear to be formatting artifacts rather than substantive changes.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 19 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 19 sells ($559M) — 6 selling insiders
- Last 180 days · read to 2026-10-040 buys · 41 sells ($774M) — 7 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-21. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AVAH's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding AVAH as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 16,322,980
- Reported value $139,887,941
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about AVAH's institutional holders → See what each manager we track holds →
Short interest (FINRA)
AVAH had 5,505,230 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
AVAH had 2.52% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 1.92 days to cover at the same settlement.
- Reported short interest (shares) 5,505,230
- Short interest (% of shares outstanding) 2.52%
- Prior settlement (shares) 5,487,469
- Reported change 0.32%
- Days to cover (reported) 1.92
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Amedisys (AMED)
- Addus HomeCare (ADUS)
- The Pennant Group (PNTG)
- Gentiva Health Services
- LHC Group (acquired by Optum)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AVAH vs…
AVEANNA HEALTHCARE HOLDINGS INC is found in…
AVAH ranks in…
Frequently asked questions
What does AVEANNA HEALTHCARE HOLDINGS INC (AVAH) do?
Aveanna Healthcare Holdings provides specialized home-based healthcare services, including clinical, rehabilitative, and supportive care. Its service offerings span private duty nursing, home health and hospice care, and the provision of durable medical equipment.
What sector is AVEANNA HEALTHCARE HOLDINGS INC (AVAH) in?
AVEANNA HEALTHCARE HOLDINGS INC (AVAH) is classified in the Health Care sector. Its industry is Home Healthcare Services. It trades on NASDAQ.
Who are AVEANNA HEALTHCARE HOLDINGS INC's (AVAH) competitors?
Notable peers of AVEANNA HEALTHCARE HOLDINGS INC (AVAH) include Amedisys, Addus HomeCare, The Pennant Group, Gentiva Health Services and LHC Group (acquired by Optum). This peer set is informational only — not financial advice.
Is AVEANNA HEALTHCARE HOLDINGS INC (AVAH) overbought or oversold right now?
AVEANNA HEALTHCARE HOLDINGS INC (AVAH) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 41, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AVAH come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.